<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<ibecs-document>
<record>
<header>
<identifier>ibc-90891</identifier>
<setSpec>1888-4008</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:title xml:lang="en">Current and future techniques for quantifying circulating tumor cells: importance in solid epithelial tumors</dc:title>
<dc:description xml:lang="en">Cancer metastasis occurs when cells shed from a primary or metastatic tumor, enter the circulation, and begin to grow in distant locations of the body. Carcinomas are derived from epithelial cells that are not normally found in circulation. The presence of circulating tumor cells (CTC) in the peripheral blood, as detected by the CellSearch(R) Circulating Tumor Cell Kit, is associated with disease free survival and decreased overall survival in patients treated for metastatic breast, colorectal or prostate cancer. The test is to be used as an aid in the monitoring of patients with metastatic breast, colorectal or prostate cancer. In our article we will evaluate other methods of analysing circulating tumor cells and their clinical application (AU)</dc:description>
<dc:creator>Maestro de las Casas, María Luisa</dc:creator>
<dc:creator>Vidaurreta Lázaro, Marta</dc:creator>
<dc:creator>Veganzones de Castro, Silvia</dc:creator>
<dc:creator>Sua Villegas, Luz Fernanda</dc:creator>
<dc:creator>Silva Pérez, Nhora María</dc:creator>
<dc:creator>Rafael Fernández, Sara</dc:creator>
<dc:language>es</dc:language>
<dc:description xml:lang="es">Las metástasis de los tumores sólido se producen cuando las células de un carcinoma primario o metastásico migran en el sistema circulatorio y proliferan en lugares distantes del organismo. Los carcinomas son de origen epithelial, y no es habitual que estas células se encuentren en el torrente circulatorio. La presencia de células tumorales circulantes (CTC) en sangre periférica detectadas con CellSearch(R) Circulating Tumor Cell System, está asociada a menor supervivencia libre de enfermedad (SLE) y menor supervivencia global (SG) en pacientes de cáncer de mama, colorrectal y de próstata metastatizante. Esta prueba sirve para ayudar en la monitorización de pacientes con cáncer de mama, colorrectal o próstata. Además, en el presente artículo revisamos otras técnicas de detección de células tumorales circulantes y su aplicabilidad (AU)</dc:description>
<dc:source>Rev. lab. clín;4(3): 163-169, jul.-sept. 2011.</dc:source>
<dc:identifier>ibc-90891</dc:identifier>
<dc:title xml:lang="es">Actualidad y futuro en las técnicas de cuantificiación de células tumorales circulantes: su importancia en tumores sólidos epiteliales</dc:title>
<dc:subject>^d1968^s22016</dc:subject>
<dc:subject>^d21034</dc:subject>
<dc:subject>^d21030</dc:subject>
<dc:subject>^d21044</dc:subject>
<dc:subject>^d20174</dc:subject>
<dc:subject>^d331</dc:subject>
<dc:subject>^d9553^s22071</dc:subject>
<dc:subject>^d11914^s22012</dc:subject>
<dc:subject>^d9555^s22016</dc:subject>
<dc:subject>^d31753^s22016</dc:subject>
<dc:subject>^d9062</dc:subject>
<dc:subject>^d9553^s22011</dc:subject>
<dc:subject>^d9553^s22044</dc:subject>
<dc:subject>^d9553^s22021</dc:subject>
<dc:subject>^d31753^s22012</dc:subject>
<dc:subject>^d1968^s22012</dc:subject>
<dc:subject>^d9555^s22053</dc:subject>
<dc:subject>^d9553^s22053</dc:subject>
<dc:subject>^d11914^s22016</dc:subject>
<dc:subject>^d9553^s22063</dc:subject>
<dc:type>article</dc:type>
<dc:date>201109</dc:date>
</metadata>
</record>
</ibecs-document>
